US stocks snap losing streak on Treasury move, solid profits
U.S. stocks rose after the Treasury announced plans to double purchases of longer-term Treasurys, easing bond market pressure. The S&P 500 gained 0.2%, ending a 3-day losing streak. Strong earnings from Estee Lauder, Target, and others also supported gains. Moderna and Merck surged on positive cancer vaccine trial results. The 10-year Treasury yield fell to 4.64% from 4.71%.
How this was made
The 30-second read
Why it matters
The Treasury buyback announcement lowers long‑term yields, providing liquidity support and boosting equity sentiment. Concurrently, strong earnings and biotech trial news deliver company‑specific catalysts, creating a mixed but overall bullish environment for U.S. equities.
Market read
Broad market rally driven by policy easing and multiple earnings beats, with notable upside in biotech and consumer sectors.
What to watch
Potential fiscal constraints limiting further Treasury purchases and the longer‑term impact of the biotech trial data on competitive pipelines.
Background
The article combines a new Treasury policy announcement with several corporate earnings and trial results that moved markets on the same day.
Ticker impact
Moderna shares surged 177% after announcing encouraging cancer‑vaccine trial results.
Further upside on follow‑on data and potential partnership announcements.
Trial results are a primary disclosure with high novelty for a biotech.
Merck jumped 12.6% on the same cancer‑vaccine trial data showing improved recurrence‑free survival.
Potential incremental gains as the data is digested and market reassesses pipeline value.
Primary news of a trial result directly affecting the company's product prospects.
Estee Lauder rallied 16.3% after reporting EPS of $0.39, beating expectations and showing accelerating revenue growth.
Likely modest further upside if guidance remains upbeat.
Earnings beat is fresh but not a large‑scale surprise.
Target rose 4.3% following better‑than‑expected quarterly profit.
Small incremental gains expected.
Standard earnings beat with modest impact.
Toll Brothers climbed 4% on better‑than‑expected quarterly results.
Modest upside possible.
Earnings beat with limited scale.
Broadcom fell 4.6%, weighing on the S&P 500 as the heaviest weight.
Further downside if broader AI hype eases.
Price move driven by sector dynamics rather than a new company‑specific event.
Market effects
Treasury’s increased bond purchases ease yield pressure, supporting equities broadly, especially consumer and biotech stocks.
U.S. markets rose while Asian indices fell, highlighting divergent regional reactions to the policy shift.
The policy move may influence global bond markets and risk appetite worldwide.
Counterpoint
If Treasury buying is insufficient, yields could rebound, pressuring growth stocks despite short‑term gains.
Key entities
- governmentU.S. Treasury Department
Announced doubling of longer‑term Treasury purchases.
- companyModerna
Biotech firm reporting positive cancer‑vaccine trial data.
